6-[(5S)-5-[3-[(methylsulfonyl)oxy]propyl]-2-oxo-3-oxazolidinyl]-2H-1,4-benzothiazin-3(4H)-one | 1220979-42-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 英文名称: 6-[(5S)-5-[3-[(methylsulfonyl)oxy]propyl]-2-oxo-3-oxazolidinyl]-2H-1,4-benzothiazin-3(4H)-one
• 英文别名: 3-[(5S)-2-oxo-3-(3-oxo-4H-1,4-benzothiazin-6-yl)-1,3-oxazolidin-5-yl]propyl methanesulfonate
• CAS: 1220979-42-9
• 化学式: C₁₅H₁₈N₂O₆S₂
• 分子量: 386.45
• InChiKey: DXVLKCSENZZCAF-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  136
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  6,7-dihydropyrido[3,2,1-ij]quinazoline-1,3 (2H,5H)-dione 、 6-[(5S)-5-[3-[(methylsulfonyl)oxy]propyl]-2-oxo-3-oxazolidinyl]-2H-1,4-benzothiazin-3(4H)-one 以the title compound was obtained as a colourless solid (48 mg; 25% yield)的产率得到2-{3-[(S)-2-oxo-3-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)-oxazolidin-5-yl]-propyl}-6,7-dihydro-5H-pyrido[3,2,1-ij]quinazoline-1,3-dione
  参考文献：
  名称：

  Quinazoline-2,4-dione derivatives

  摘要：

  本发明涉及式(I)的抗菌化合物，其中R1为H、卤素、(C1-C3)烷基或(C1-C3)烷氧基；R2为H、卤素、(C1-C3)烷基、(C1-C3)烷氧基或吡咯烷-1-基；R3为H、卤素、(C1-C3)烷基、(C1-C3)烷氧基、乙烯基或2-甲氧羰基乙烯基，或R2和R3与它们所带的两个碳原子形成苯环；R4为H、卤素、(C1-C3)烷基或(C1-C3)烷氧基；R5为H、(C1-C3)烷基或环丙基，或R4和R5共同形成—CH2CH2CH2—基团；A为二价基团—CH2—、—CH2CH2—、#—CH(OH)CH2—*、#—CH2N(R6)—*和—CH2NHCH2—，其中#表示连接到可选取代的(喹唑啉-2,4-二酮-3-基)甲基残基的连接点，*表示连接到取代的(噁唑烷-4-基)甲基残基的连接点；R6为H或乙酰基；Y为CH或N；Q为O或S；以及这些化合物的盐。

  公开号：

  US08916573B2

文献信息

• [EN] QUINAZOLINE-2,4-DIONE DERIVATIVES<br/>[FR] DÉRIVÉS DE QUINAZOLINE-2,4-DIONE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2013021363A1

  公开（公告）日：2013-02-14

  The invention relates to antibacterial compounds of formula (I), wherein R1 is H, halogen, (C1-C3)alkyl or (C1-C3)alkoxy; R2 is H, halogen, (C1-C3)alkyl, (C1-C3)alkoxy or pyrrolidin-l-yl; R3 is H, halogen, (C1-C3)alkyl, (C1-C3)alkoxy, vinyl or 2-methoxycarbonylvinyl or R2 and R3 together with the two carbon atoms which bear them form a phenyl ring; R4 is H, halogen, (C1-C3)alkyl or (C1-C3)alkoxy and R5 is H, (C1-C3)alkyl or cyclopropyl, or R4 and R5 form together a -CH2CH2CH2- group; A is the divalent group -CH2-, -CH2CH2-, #-CH(OH)CH2-*, #-CH2N(R6)-* or -CH2NHCH2-, wherein # indicates the point of attachment to the optionally substituted (quinazoline-2,4-dione-3-yl)methyl residue and * represents the point of attachment to the substituted (oxazolidinon-4-yl)methyl residue; R6 is H or acetyl; Y is CH or N; and Q is O or S; and salts of such compounds.

  该发明涉及式(I)的抗菌化合物，其中R1为H、卤素、(C1-C3)烷基或(C1-C3)氧烷基；R2为H、卤素、(C1-C3)烷基、(C1-C3)氧烷基或吡咯烷-1-基；R3为H、卤素、(C1-C3)烷基、(C1-C3)氧烷基、乙烯基或2-甲氧羰基乙烯基，或者R2和R3与它们所连接的两个碳原子一起形成苯环；R4为H、卤素、(C1-C3)烷基或(C1-C3)氧烷基，R5为H、(C1-C3)烷基或环丙基，或者R4和R5一起形成一个-CH2CH2CH2-基团；A为二价基团-CH2-、-CH2CH2-、#-CH(OH)CH2-*、#-CH2N(R6)-*或-CH2NHCH2-，其中#表示可选择取代的(喹唑啉-2,4-二酮-3-基)甲基残基的连接点，*表示取代的(噁唑烷酮-4-基)甲基残基的连接点；R6为H或乙酰基；Y为CH或N；Q为O或S；以及这类化合物的盐。
• [EN] TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS<br/>[FR] COMPOSÉS ANTIBIOTIQUES OXAZOLIDINONE TRICYCLIQUE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2010041194A1

  公开（公告）日：2010-04-15

  The invention relates to antibacterial compounds of formula (I) wherein “-----” is a bond or is absent, V is CH, CR 6 or N; R 0 is H or, if “-----” is a bond, may also be alkoxy; R 1 is notably H or halogen; U is CH or N when “-----” is a bond, or, if “-----” is absent, U is CH 2, NH or NR 9; R 2 is H, alkylcarbonyl or –CH 2 -R 3; R 3 is H, alkyl or hydroxyalkyl; R 4 is H or, if n is not 0 and R 5 is H, may also be OH; R 5 is H, alkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, carboxy or alkoxycarbonyl; R 6 is hydroxyalkyl, carboxy, alkoxycarbonyl or -(CH 2 ) q -NR 7 R 8, q being 1, 2 or 3 and each of R 7 and R 8 independently being H or alkyl or R 7 and R 8 forming with the N atom bearing them a ring; R 9 is alkyl or hydroxyalkyl; A is -(CH 2 ) p -, -CH 2 CH 2 CH(OH)- or -COCH 2 CH(OH)-; G is substituted phenyl or G 1 or G 2, wherein Q is O or S and X is CH or N; and Y 1, Y 2 and Y 3 may each be CH or N; and n is 0 when A is -CH 2 CH 2 CH(OH)- or -COCH 2 CH(OH)-, and n is 0, 1 or 2 when A is -(CH 2 ) p -, p being 1, 2, 3 or 4, with the proviso that the sum of n and p is then 2, 3 or 4; and to salts of such compounds.

  该发明涉及式(I)的抗菌化合物，其中“-----”是键或不存在，V是CH，CR 6或N; R 0是H或如果“-----”是键，则也可以是烷氧基; R 1主要是H或卤素; 当“-----”是键时，U是CH或N，或者如果“-----”不存在，则U是CH 2，NH或NR 9; R 2是H，烷基羰基或-CH 2 -R 3; R 3是H，烷基或羟基烷基; R 4是H或如果n不为0且R 5为H，则也可以是OH; R 5是H，烷基，羟基烷基，氨基烷基，烷氧基烷基，羧基或烷氧羰基; R 6是羟基烷基，羧基，烷氧羰基或-(CH 2 ) q -NR 7 R 8，其中q为1、2或3，且R 7和R 8中的每一个独立地是H或烷基，或R 7和R 8与携带它们的N原子形成一个环; R 9是烷基或羟基烷基; A是-(CH 2 ) p-，-CH 2 CH 2 CH(OH)-或-COCH 2 CH(OH)-; G是取代苯基或G 1或G 2，其中Q是O或S，X是CH或N; Y 1、Y 2和Y 3每个可以是CH或N; 当A为-CH 2 CH 2 CH(OH)-或-COCH 2 CH(OH)-时，n为0，当A为-(CH 2 ) p-，p为1、2、3或4时，n为0、1或2，但n和p的总和为2、3或4; 以及这些化合物的盐。
• TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS
  申请人：Hubschwerlen Christian

  公开号：US20110195961A1

  公开（公告）日：2011-08-11

  The invention relates to antibacterial compounds of formula I wherein is a bond or is absent, V is CH, CR 6 or N; R 0 is H or, if is a bond, may also be alkoxy; R 1 is notably H or halogen; U is CH or N when is a bond, or, if is absent, U is CH 2 , NH or NR 9 ; R 2 is H, alkylcarbonyl or —CH 2 —R 3 ; R 3 is H, alkyl or hydroxyalkyl; R 4 is H or, if n is not 0 and R 5 is H, may also be OH; R 5 is H, alkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, carboxy or alkoxycarbonyl; R 6 is hydroxyalkyl, carboxy, alkoxycarbonyl or —(CH 2 ) q —NR 7 R 8 , q being 1, 2 or 3 and each of R 7 and R 8 independently being H or alkyl or R 7 and R 8 forming with the N atom bearing them a ring; R 9 is alkyl or hydroxyalkyl; A is —(CH 2 ) p —, —CH 2 CH 2 CH(OH)— or —COCH 2 CH(OH)—; G is substituted phenyl or G 1 or G 2 wherein Q is O or S and X is CH or N; and Y 1 , Y 2 and Y 3 may each be CH or N; and n is 0 when A is —CH 2 CH 2 CH(OH)— or —COCH 2 CH(OH)—, and n is 0, 1 or 2 when A is —(CH 2 ) p —, p being 1, 2, 3 or 4, with the proviso that the sum of n and p is then 2, 3 or 4; and to salts of such compounds.

  该发明涉及式I的抗菌化合物，其中： - 当V为CH或N时，U为CH或N，R1为H或卤素，R2为H、烷基羰基或—CH2—R3，R3为H或烷基羟基，R4为H或OH（当n不为0且R5为H时），R5为H、烷基、羟基烷基、氨基烷基、烷氧基烷基、羧基或烷氧羰基，R6为羟基烷基、羧基、烷氧羰基或—(CH2)q—NR7R8，其中q为1、2或3，且R7和R8各自独立地为H或烷基，或者R7和R8与它们所带的N原子形成一个环； - 当V为CR6时，U为CH2、NH或NR9，R0为H或烷氧基，R1为H或卤素，R2为H、烷基羰基或—CH2—R3，R3为H或烷基羟基，R4为H或OH（当n不为0且R5为H时），R5为H、烷基、羟基烷基、氨基烷基、烷氧基烷基、羧基或烷氧羰基，R6为羟基烷基、羧基、烷氧羰基或—(CH2)q—NR7R8，其中q为1、2或3，且R7和R8各自独立地为H或烷基，或者R7和R8与它们所带的N原子形成一个环； - 当V为一条键时，U为CH或N，R0为H或烷氧基，R1为H或卤素，R2为H、烷基羰基或—CH2—R3，R3为H或烷基羟基，R4为H或OH（当n不为0且R5为H时），R5为H、烷基、羟基烷基、氨基烷基、烷氧基烷基、羧基或烷氧羰基，R6为羟基烷基、羧基、烷氧羰基或—(CH2)q—NR7R8，其中q为1、2或3，且R7和R8各自独立地为H或烷基，或者R7和R8与它们所带的N原子形成一个环；A为—(CH2)p—、—CH2CH2CH(OH)—或—COCH2CH(OH)—，G为取代苯基或G1或G2，其中Q为O或S，X为CH或N，Y1、Y2和Y3各自可以为CH或N；n当A为—CH2CH2CH(OH)—或—COCH2CH(OH)—时为0，当A为—(CH2)p—时，n为0、1或2，p为1、2、3或4，但n和p的和必须为2、3或4；以及这些化合物的盐。
• Quinazoline-2,4-dione derivatives
  申请人：Hubschwerlen Christian

  公开号：US08916573B2

  公开（公告）日：2014-12-23

  The invention relates to antibacterial compounds of formula (I), wherein R1 is H, halogen, (C1-C3)alkyl or (C1-C3)alkoxy; R2 is H, halogen, (C1-C3)alkyl, (C1-C3)alkoxy or pyrrolidin-1-yl; R3 is H, halogen, (C1-C3)alkyl, (C1-C3)alkoxy, vinyl or 2-methoxycarbonyvinyl or R2 and R3 together with the two carbon atoms which bear them form a phenyl ring; R4 is H, halogen, (C1-C3)alkyl or (C1-C3)alkoxy; and R5 is H, (C1-C3)alkyl or cyclopropyl, or R4 and R5form together a —CH2CH2CH2— group; A is the divalent group —CH2—, —CH2CH2—, #—CH(OH)CH2—*, #—CH2N(R6)—* and —CH2NHCH2—, wherein # indicates the point of attachment to the optionally substituted (quinazoline-2,4-dione-3-yl)methyl residue and * represents the point of attachment to the substituted (oxazolidinon-4-yl)methyl residue; R6 is H or acetyl; Y is CH or N; and Q is O or S; and salts of such compounds.

  本发明涉及式(I)的抗菌化合物，其中R1为H、卤素、(C1-C3)烷基或(C1-C3)烷氧基；R2为H、卤素、(C1-C3)烷基、(C1-C3)烷氧基或吡咯烷-1-基；R3为H、卤素、(C1-C3)烷基、(C1-C3)烷氧基、乙烯基或2-甲氧羰基乙烯基，或R2和R3与它们所带的两个碳原子形成苯环；R4为H、卤素、(C1-C3)烷基或(C1-C3)烷氧基；R5为H、(C1-C3)烷基或环丙基，或R4和R5共同形成—CH2CH2CH2—基团；A为二价基团—CH2—、—CH2CH2—、#—CH(OH)CH2—*、#—CH2N(R6)—*和—CH2NHCH2—，其中#表示连接到可选取代的(喹唑啉-2,4-二酮-3-基)甲基残基的连接点，*表示连接到取代的(噁唑烷-4-基)甲基残基的连接点；R6为H或乙酰基；Y为CH或N；Q为O或S；以及这些化合物的盐。
• US8618092B2
  申请人：——

  公开号：US8618092B2

  公开（公告）日：2013-12-31